跳至主要内容
临床试验/ACTRN12618001447246
ACTRN12618001447246已完成4 期

Efficacy of InferrinTM and lactoferrin on symptoms of Irritable Bowel Syndrome. A randomized double-blind placebo-controlled study.

RDC Global Pty Ltd0 个研究点目标入组 69 人开始时间: 2018年8月28日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
69

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Males and females 18 years and over
  • Patients meeting the Rome IV irritable bowel syndrome (IBS) diagnostic criteria. IBS is defined as recurrent abdominal pain or discomfort at least 1 days/week in last 3 months (onset at least 6 months ago) associated with two or more of the following:
  • Related to defecation
  • Associated with a change in frequency of stool
  • Associated with a change in form (appearance) of stool
  • Able to provide informed consent
  • Females using a prescribed form of birth control (e.g. oral contraceptive)
  • Normal dietary habits (no FODMAP diet, elimination diet, vegan diet, etc) with a minimum 2-month period of self-reported dietary stability.
  • Otherwise healthy
  • Agree to not use any other dietary supplements which may impact gastrointestinal tract function during the study period

排除标准

  • Intake of lactoferrin containing products including sports nutrition products within the last 2 years
  • Concomitant treatment during the study (including screening phase) with any medication that could influence the gastrointestinal
  • Regular intake of nonsteroidal anti-inflammatory drugs incl. COX-2-inhibitors (exception: acetylsalicylic acid for cardiovascular prevention up to 100 mg daily)
  • Regular intake of medications that could influence immune function
  • Patients with known hypersensitivity to any component of the trial drugs – including cow milk allergy
  • History of eating disorders
  • Patients with a history of diseases with abdominal symptoms that can resemble IBS
  • Presence of any other acute or chronic gastrointestinal disorder
  • History of abdominal surgery (cholecystectomy and appendectomy can be tolerated when performed at least one year previously)
  • Unstable or serious illness (e.g. kidney, liver, GIT, heart conditions, diabetes, thyroid gland function Malignancy) ?
  • Pregnant or breastfeeding mothers (females who cannot rule out or suspect they may be pregnant will be directed to their GP for a pregnancy blood test)
  • Malignancy or treatment for malignancy within the previous 2 years ?
  • Receiving/ prescribed coumadin (Warfarin), heparin, dalteparin, enoxaparin or other ?anticoagulation therapy including low dose aspirin ?
  • Active smokers, nicotine, alcohol, drug abuse ?
  • Chronic past and/or current alcohol use (>14 alcoholic drinks week) ?
  • Any condition which in the opinion of the investigator makes the participant unsuitable for ?inclusion
  • Participants who have participated in any other clinical trial during the past 3 months

研究者

相似试验